United States Biotechnology & Medical Research

Parabilis Medicines Inc (PBLS)

Track

Track

Parabilis Medicines Inc. experienced significant buying activity over the past ninety days, totaling approximately $6.9 million in net acquisitions. RA Capital Management, L.P. remains the primary purchaser, consistently increasing its stake. This accumulation occurs amid a 51.7% stock price surge, despite a recent negative earnings report showing a substantial EPS miss.
Ticker: PBLS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Parabilis Medicines Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
373.30
Quantity 54,786 -7.0%
Value US$4,831,818
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
334.12
Quantity 2,976 +5.0%
Value US$377,320
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
219.71
Quantity 80,351 -30.2%
Value US$1,261,482
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
27.96
Quantity 21,696 +0.1%
Value US$606,620
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
27.72
Quantity 32,987 +0.1%
Value US$914,400
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
27.13
Quantity 98,433 +0.4%
Value US$2,670,487
SEBULSKY ALAN Non-Executive Director
Transaction date
Purchase
Price
27.10
Quantity 4,065 +15.7%
Value US$110,146
SEBULSKY ALAN Non-Executive Director
Transaction date
Purchase
Price
26.00
Quantity 5,000 +23.9%
Value US$129,989
SEBULSKY ALAN Non-Executive Director
Transaction date
Purchase
Price
27.67
Quantity 8,435 +67.5%
Value US$233,393
2.3
Levy Guy Large shareholder
Transaction date
Purchase
Price
20.00
Quantity 125,000 +23.7%
Value US$2,500,000
2.3
Levy Guy Large shareholder
Transaction date
Purchase
Price
20.00
Quantity 375,000 +57.5%
Value US$7,500,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
20.00
Quantity 1,460,397 +122.9%
Value US$29,207,940
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
20.00
Quantity 19,728,353 +300.9%
Value US$394,567,060
SEBULSKY ALAN Non-Executive Director
Transaction date
Purchase
Price
20.00
Quantity 12,500 +inf%
Value US$250,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-22 2026-07-22 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
54,786 -7.0%
373.30
US$4,831,818 		54,786 -7.0% 373.30 US$4,831,818
2026-07-22 2026-07-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
2,976 +5.0%
334.12
US$377,320 		2,976 +5.0% 334.12 US$377,320
2026-07-22 2026-07-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
80,351 -30.2%
219.71
US$1,261,482 		80,351 -30.2% 219.71 US$1,261,482
2026-07-22 2026-07-21 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
21,696 +0.1%
27.96
US$606,620 		21,696 +0.1% 27.96 US$606,620
2026-07-22 2026-07-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
32,987 +0.1%
27.72
US$914,400 		32,987 +0.1% 27.72 US$914,400
2026-07-22 2026-07-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
98,433 +0.4%
27.13
US$2,670,487 		98,433 +0.4% 27.13 US$2,670,487
2026-06-16 2026-06-15 B Purchase
SEBULSKY ALAN
Non-Executive Director
4,065 +15.7%
27.10
US$110,146 		4,065 +15.7% 27.10 US$110,146
2026-06-16 2026-06-15 B Purchase
SEBULSKY ALAN
Non-Executive Director
5,000 +23.9%
26.00
US$129,989 		5,000 +23.9% 26.00 US$129,989
2026-06-16 2026-06-12 B Purchase
SEBULSKY ALAN
Non-Executive Director
8,435 +67.5%
27.67
US$233,393 		8,435 +67.5% 27.67 US$233,393
2026-06-29 2026-06-11 B Purchase
2.3
Levy Guy
Large shareholder
125,000 +23.7%
20.00
US$2,500,000 		125,000 +23.7% 20.00 US$2,500,000
2026-06-29 2026-06-11 B Purchase
2.3
Levy Guy
Large shareholder
375,000 +57.5%
20.00
US$7,500,000 		375,000 +57.5% 20.00 US$7,500,000
2026-06-15 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,460,397 +122.9%
20.00
US$29,207,940 		1,460,397 +122.9% 20.00 US$29,207,940
2026-06-15 2026-06-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
19,728,353 +300.9%
20.00
US$394,567,060 		19,728,353 +300.9% 20.00 US$394,567,060
2026-06-15 2026-06-11 B Purchase
SEBULSKY ALAN
Non-Executive Director
12,500 +inf%
20.00
US$250,000 		12,500 +inf% 20.00 US$250,000
Explore more

More insider trading research around Parabilis Medicines Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America